FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911625131> ?p ?o ?g. }

• W2911625131 abstract "Due to the surge in type 2 diabetes mellitus (T2DM), treatments for chronic metabolic dysregulations with fewer side-effects are sought. Lycii Cortex (LyC), a traditional Chinese Medicine (TCM) herb has a long history of being widely prescribed to treat T2DM as alternative medicine; however, the bioactive molecules and working mechanism remained unknown. Previous studies revealed kukoamine B (KB) as a major and featured compound for LyC with bioactivities for anti-oxidation and acute inflammation, which may be related to anti-diabetes properties. This study aims to understand the efficacy and the mode of action of KB in the diabetic (db/db) mouse model using a metabolomics approach. Parallel comparison was conducted using the first-line anti-diabetic drugs, metformin and rosligtazone, as positive controls. The db/db mice were treated with KB (50 mg kg−1 day−1) for 9 weeks. Bodyweight and fasting blood glucose were monitored every 5 and 7 days, respectively. Metabolomics and high-throughput molecular approaches, including lipidomics, targeted metabolomics (Biocrates p180), and cytokine profiling were applied to measure the alteration of serum metabolites and inflammatory biomarkers between different treatments versus control (db/db mice treated with vehicle). After 9 weeks of treatment, KB lowered blood glucose, without the adverse effects of bodyweight gain and hepatomegaly shown after rosiglitazone treatment. Lipidomics analysis revealed that KB reduced levels of circulating triglycerides, cholesterol, phosphatidylethanolamine, and increased levels of phosphatidylcholines. KB also increased acylcarnitines, and reduced systemic inflammation (cytokine array). Pathway analysis suggested that KB may regulate nuclear transcription factors (e.g., NF-κB and/or PPAR) to reduce inflammation and facilitate a shift toward metabolic and inflammatory homeostasis. Comparison of KB with first-line drugs suggests that rosiglitazone may over-regulate lipid metabolism and anti-inflammatory responses, which may be associated with adverse side effects, while metformin had less impact on lipid and anti-inflammation profiles. Our research from holistic and systemic views supports the conclusion that KB is the bioactive compound of LyC for managing T2DM, and suggests KB as a nutraceutical or pharmaceutical candidate for T2D treatment. In addition, our research provides insights related to metformin and rosiglitazone action, beyond lowering blood glucose." @default.
• W2911625131 created "2019-02-21" @default.
• W2911625131 creator A5002187415 @default.
• W2911625131 creator A5018262531 @default.
• W2911625131 creator A5028457441 @default.
• W2911625131 creator A5042079141 @default.
• W2911625131 creator A5054530975 @default.
• W2911625131 creator A5058152911 @default.
• W2911625131 creator A5058796422 @default.
• W2911625131 creator A5077627182 @default.
• W2911625131 creator A5089143039 @default.
• W2911625131 date "2019-01-22" @default.
• W2911625131 modified "2023-09-24" @default.
• W2911625131 title "A Metabolomics Approach to Investigate Kukoamine B—A Potent Natural Product With Anti-diabetic Properties" @default.
• W2911625131 cites W172609984 @default.
• W2911625131 cites W1797956629 @default.
• W2911625131 cites W1847201797 @default.
• W2911625131 cites W1963702345 @default.
• W2911625131 cites W1964498676 @default.
• W2911625131 cites W1967161323 @default.
• W2911625131 cites W1972123715 @default.
• W2911625131 cites W1972980481 @default.
• W2911625131 cites W1982753924 @default.
• W2911625131 cites W1987064503 @default.
• W2911625131 cites W1999637124 @default.
• W2911625131 cites W2007543394 @default.
• W2911625131 cites W2012531860 @default.
• W2911625131 cites W2017109450 @default.
• W2911625131 cites W2027972953 @default.
• W2911625131 cites W2028710564 @default.
• W2911625131 cites W2029784301 @default.
• W2911625131 cites W2030507620 @default.
• W2911625131 cites W2032880834 @default.
• W2911625131 cites W2037136746 @default.
• W2911625131 cites W2043425632 @default.
• W2911625131 cites W2046662085 @default.
• W2911625131 cites W2049934030 @default.
• W2911625131 cites W2053157346 @default.
• W2911625131 cites W2054115426 @default.
• W2911625131 cites W2057858725 @default.
• W2911625131 cites W2059443125 @default.
• W2911625131 cites W2062756785 @default.
• W2911625131 cites W2066096701 @default.
• W2911625131 cites W2066207556 @default.
• W2911625131 cites W2069671127 @default.
• W2911625131 cites W2071259051 @default.
• W2911625131 cites W2072972071 @default.
• W2911625131 cites W2073578030 @default.
• W2911625131 cites W2074742267 @default.
• W2911625131 cites W2080580057 @default.
• W2911625131 cites W2102762614 @default.
• W2911625131 cites W2106604484 @default.
• W2911625131 cites W2109221964 @default.
• W2911625131 cites W2119654384 @default.
• W2911625131 cites W2124304641 @default.
• W2911625131 cites W2132279891 @default.
• W2911625131 cites W2135977165 @default.
• W2911625131 cites W2138521217 @default.
• W2911625131 cites W2142228799 @default.
• W2911625131 cites W2142504521 @default.
• W2911625131 cites W2143481724 @default.
• W2911625131 cites W2144770293 @default.
• W2911625131 cites W2148403724 @default.
• W2911625131 cites W2152993057 @default.
• W2911625131 cites W2154024784 @default.
• W2911625131 cites W2158958532 @default.
• W2911625131 cites W2168731601 @default.
• W2911625131 cites W2266533745 @default.
• W2911625131 cites W2304481239 @default.
• W2911625131 cites W2324377060 @default.
• W2911625131 cites W2418833639 @default.
• W2911625131 cites W2485221707 @default.
• W2911625131 cites W2502845086 @default.
• W2911625131 cites W2520708667 @default.
• W2911625131 cites W2527179716 @default.
• W2911625131 cites W2531417571 @default.
• W2911625131 cites W2539494034 @default.
• W2911625131 cites W2593927310 @default.
• W2911625131 cites W2615836991 @default.
• W2911625131 cites W2728022110 @default.
• W2911625131 cites W845801691 @default.
• W2911625131 doi "https://doi.org/10.3389/fphar.2018.01575" @default.
• W2911625131 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6350459" @default.
• W2911625131 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30723413" @default.
• W2911625131 hasPublicationYear "2019" @default.
• W2911625131 type Work @default.
• W2911625131 sameAs 2911625131 @default.
• W2911625131 citedByCount "18" @default.
• W2911625131 countsByYear W29116251312019 @default.
• W2911625131 countsByYear W29116251312020 @default.
• W2911625131 countsByYear W29116251312021 @default.
• W2911625131 countsByYear W29116251312022 @default.
• W2911625131 countsByYear W29116251312023 @default.
• W2911625131 crossrefType "journal-article" @default.
• W2911625131 hasAuthorship W2911625131A5002187415 @default.
• W2911625131 hasAuthorship W2911625131A5018262531 @default.
• W2911625131 hasAuthorship W2911625131A5028457441 @default.
• W2911625131 hasAuthorship W2911625131A5042079141 @default.
• W2911625131 hasAuthorship W2911625131A5054530975 @default.
• W2911625131 hasAuthorship W2911625131A5058152911 @default.

• next